Drugs / Rabeprazole
Rabeprazole
also known as
Rabeprazole sodium · Pariet · Aciphex · E3810 · Pariet (rabeprazole) · Aciphex sprinkle · E-3810 (PPI) · E-3810 SODIUM · +15 more
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | ACIPHEX | — | 2002-02-12 – 2008-06-30 | fda.gov ↗ |
| Approved | US (FDA) | ACIPHEX | — | 1999-08-19 | fda.gov ↗ |
Trials 151 · started per year
today
US approved 1999
1
2
2
6
7
10
3
3
9
8
8
4
5
7
5
7
4
4
4
7
10
4
12
8
3
3
5
199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 163 trials | ||||||
| Phase 1 | NCT07608666 | Jul → Dec 2026 expected | myelofibrosis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07597928 | May → Sep 2026 expected | — | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT07563894 | Apr → Jun 2026 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT07284173 | Nov → Dec 2025 overdue | — | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07141381 | Aug → Dec 2025 | — | Voronoi, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06417229 | May 2024 → Feb 2025 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06264440 | Feb → Jun 2024 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT06105983 | Nov 2023 → Jul 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06054464 | Sep → Nov 2023 | — | PMV Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06399315 | Jul 2023 → Jun 2025 | acute myeloid leukemia | Lomond Therapeutics Holdings, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05918822 | Jul → Aug 2023 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT05899829 | Jun → Aug 2023 | — | Bellus Health Inc. - a GSK company | Completed | No outcome recorded |
| Phase 1 | NCT05930119 | Mar → Aug 2023 | intrahepatic cholangiocarcinoma | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05699070 | Feb → Apr 2023 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT05630677 | Nov 2022 → Feb 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05571787 | Jul → Sep 2022 | lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05446142 | Jul → Sep 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05380947 | Jun → Sep 2022 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05602597 | Jun → Aug 2022 | lymphoma | Hutchmed | Completed | No outcome recorded |
| Phase 1 | NCT05330858 | Mar → Jun 2022 | — | Alumis Inc | Completed | No outcome recorded |
| Phase 1 | NCT04703868 | Jan → Jun 2021 | gastroesophageal reflux disease | Yungjin Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04622358 | Dec 2020 → Mar 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04565574 | Oct 2020 → Mar 2021 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04564040 | Oct → Dec 2020 | COVID-19, mantle cell lymphoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04564612 | Sep 2020 → Sep 2022 | — | Biogen | Completed | No outcome recorded |
| Phase 1 | NCT04494243 | Aug 2020 → Jan 2021 | gastroesophageal reflux disease | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04489797 | Jul → Aug 2020 | infectious disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04488016 | Jun 2020 → Jan 2021 | B-cell neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04435483 | May → Jun 2020 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04211545 | Oct → Dec 2019 | — | Celgene Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03979248 | May → Jul 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03789032 | Oct → Nov 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03530995 | Apr 2018 → Feb 2019 | autoimmune disease | Kadmon Corporation, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03464058 | Mar → Oct 2018 | — | Boston Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03220191 | Jul → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03290703 | Apr 2017 → Oct 2018 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02655614 | May 2016 → Mar 2020 | amyotrophic lateral sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02569554 | Dec 2015 → Apr 2016 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02509923 | Jul 2015 → Mar 2016 | — | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02475161 | Jun → Jul 2015 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT02311946 | Jan → Apr 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02524210 | May 2014 → May 2015 | — | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 1 | NCT02097329 | Apr → Jun 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01954043 | Dec 2013 → Feb 2016 | cancer | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01918176 | Sep → Dec 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01772290 | Feb → May 2013 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01759875 | Jan 2013 → Jan 2014 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01702506 | Oct 2012 → Jan 2013 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01857609 | Aug → Dec 2012 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT01277718 | Jan → Feb 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01287091 | Oct 2010 → Feb 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01186497 | Aug → Nov 2010 | — | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00989300 | Nov 2009 → Mar 2010 | — | Janssen Cilag S.A.S. | Completed | No outcome recorded |
| Phase 1 | NCT00999128 | Oct 2009 → Feb 2010 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00855361 | Jul 2009 → Dec 2011 | gastroesophageal reflux disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01101646 | Aug → Sep 2008 | gastroesophageal reflux disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00747695 | Mar 2008 → Sep 2009 | gastroesophageal reflux disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 1 | NCT00747526 | Dec 2007 → Feb 2012 | gastroesophageal reflux disease | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01699113 | Aug 2006 → Jun 2007 | gastrin secretion abnormality | Trio Medicines Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00378287 | Oct → Dec 2005 | gastroesophageal reflux disease | Janssen-Ortho Inc., Canada | Completed | No outcome recorded |
| Phase 1 | NCT00649194 | Aug 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648349 | May → Jun 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00649493 | May → Jun 2003 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05407675 | Aug 2022 → Aug 2024 | cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07076914 | Oct 2025 → Jan 2028 expected | non-small cell lung carcinoma, small cell lung carcinoma | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06076694 | Jun → Sep 2022 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01202071 | Sep → Dec 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01089543 | Apr 2010 → Aug 2011 | dyspepsia | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01136317 | Apr → Jul 2010 | gastroesophageal reflux disease | Nantes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00132496 | Aug 2005 → May 2006 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00222170 | May 2005 → May 2007 | gastroesophageal reflux disease | University of Kansas | Completed | No outcome recorded |
| Phase 2 | NCT00165841 | Oct 2004 → Dec 2005 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00199953 | Jun 2002 → Dec 2007 | — | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT01398410 | Dec 2011 → Dec 2013 | active peptic ulcer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT01397448 | Jul 2011 → Mar 2013 | active peptic ulcer disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00770913 | Oct 2008 → Nov 2009 | peptic esophagitis | Eisai Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00197418 | Aug 2003 → ? | Helicobacter pylori infectious disease, duodenal ulcer, gastric ulcer, gastritis | Hamamatsu University | Unknown | No outcome recorded |
| Phase 2/3 | NCT00204672 | Oct 2000 → Sep 2005 | asthma | University of Utah | Completed | No outcome recorded |
| Phase 320 trials | ||||||
| Phase 3 | NCT04215653 | Jan 2020 → Feb 2021 | duodenal ulcer | Sihuan Pharmaceutical Holdings Group Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT02037477 | Jan → Mar 2014 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT02135107 | Sep 2013 → May 2016 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04001400 | Oct 2012 → May 2014 | esophageal disorder | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00992589 | Nov 2009 → Nov 2011 | gastroesophageal reflux disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00911534 | Jan → Jul 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00787891 | Jan 2009 → Jan 2011 | gastroesophageal reflux disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00838526 | Aug 2008 → Jul 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00839306 | Aug 2008 → Aug 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00658775 | Feb 2008 → Sep 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00658632 | Feb 2008 → Apr 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00658528 | Feb 2008 → Sep 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00236184 | Oct 2005 → Mar 2006 | dyspepsia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00236197 | Oct 2005 → Mar 2006 | dyspepsia | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00165672 | May → Oct 2005 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00165646 | Sep 2004 → Oct 2005 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00553449 | Jul 2004 → Sep 2005 | dyspepsia, gastroesophageal reflux disease | Janssen-Ortho Inc., Canada | Completed | No outcome recorded |
| Phase 3 | NCT00214552 | Sep 2002 → Mar 2005 | asthma, gastroesophageal reflux disease | Associated Scientists to Help Minimize Allergies | Completed | No outcome recorded |
| Phase 3 | NCT00236392 | Oct 2001 → Oct 2002 | dyspepsia, gastroesophageal reflux disease | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 3 | NCT00132171 | Jan → Dec 2001 | Helicobacter pylori infectious disease, chronic gastritis, duodenal ulcer, dyspepsia +1 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Completed | No outcome recorded |
| Phase 436 trials | ||||||
| Phase 4 | NCT07611162 | May 2026 → May 2030 expected | gastroesophageal reflux disease | University of Mons | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07471867 | Apr 2026 → Jul 2028 expected | coronary artery disorder | Yonsei University | Recruiting | No outcome recorded |
| Phase 4 | NCT05624229 | Oct 2023 → Dec 2025 overdue | esophageal varices with bleeding | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05419674 | Aug 2022 → Aug 2023 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05332444 | Apr 2022 → Dec 2026 expected | Helicobacter pylori infectious disease | National Taiwan University Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05061732 | Sep 2021 → Jun 2026 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05014685 | Aug 2021 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04157881 | Jan 2020 → Jan 2022 | atrial fibrillation, venous thromboembolism | Population Health Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT03897244 | May 2019 → Feb 2025 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03616405 | Apr → Nov 2019 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03565484 | Jan 2019 → May 2020 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03037606 | Aug 2017 → Dec 2018 | gastroesophageal reflux disease | Neutec Ar-Ge San ve Tic A.Ş | Completed | No outcome recorded |
| Phase 4 | NCT03134378 | Oct 2016 → May 2017 | Helicobacter pylori infectious disease | Indonesia University | Unknown | No outcome recorded |
| Phase 4 | NCT02934152 | Oct 2016 → Sep 2019 | gastroesophageal reflux disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02490839 | Jul 2015 → Nov 2018 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02483715 | Jul 2015 → Mar 2018 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02541786 | Jan → Jun 2015 | Helicobacter pylori infectious disease | Kaohsiung Medical University | Completed | No outcome recorded |
| Phase 4 | NCT02635191 | Mar 2014 → Mar 2016 | Helicobacter pylori infectious disease | Beijing Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01922765 | Aug 2013 → Feb 2014 | peptic ulcer disease | The Catholic University of Korea | Unknown | No outcome recorded |
| Phase 4 | NCT01860482 | Apr 2013 → May 2015 | peptic esophagitis | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT02703896 | Jan 2012 | lung disorder | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT01566643 | Jan 2011 → Dec 2012 | Helicobacter pylori infectious disease | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01265069 | Nov 2010 → Jun 2013 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01219764 | Oct 2010 → Mar 2013 | Helicobacter pylori infectious disease | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT01163435 | Aug 2010 → Jul 2013 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00861640 | Mar 2009 → Mar 2010 | — | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01023360 | May 2008 → Oct 2010 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00844675 | Oct 2007 → Dec 2011 | gastric adenocarcinoma, tubular adenocarcinoma | The Catholic University of Korea | Completed | No outcome recorded |
| Phase 4 | NCT01008696 | May 2007 → Aug 2008 | esophagitis | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00838682 | Apr 2006 → Jan 2009 | peptic ulcer disease | The Catholic University of Korea | Terminated | No outcome recorded |
| Phase 4 | NCT00220857 | Sep 2005 → Sep 2007 | — | Temple University | Completed | No outcome recorded |
| Phase 4 | NCT00216450 | Oct 2004 → Feb 2006 | Helicobacter pylori infectious disease, primary bacterial infectious disease | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Completed | No outcome recorded |
| Phase 4 | NCT00287391 | Sep 2004 → Dec 2006 | gastroesophageal reflux disease, insomnia | University of North Carolina | Completed | No outcome recorded |
| Phase 4 | NCT00304421 | Jan 2004 → Sep 2007 | gastroesophageal reflux disease | VA Greater Los Angeles Healthcare System | Completed | No outcome recorded |
| Phase 4 | NCT00216489 | Mar 2003 → Nov 2005 | dyspepsia, gastroesophageal reflux disease | Janssen Cilag Pharmaceutica S.A.C.I., Greece | Completed | No outcome recorded |
| Phase 4 | NCT00237367 | ? → Apr 2005 | gastroesophageal reflux disease | PriCara, Unit of Ortho-McNeil, Inc. | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT06481371 | Jun 2024 → Feb 2025 | depressive disorder, dyspepsia | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT05364619 | Aug 2022 → Dec 2024 | Helicobacter pylori infectious disease | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT05226819 | Feb → Sep 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital of Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT04923113 | Jun 2021 → Jan 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| — | NCT07211880 | Dec 2019 → Dec 2020 | Helicobacter pylori infectious disease, gastric cancer | Zero Helicobacter IGAN Network | Completed | No outcome recorded |
| — | NCT03802318 | Jan 2019 → Dec 2020 | Helicobacter pylori infectious disease, bacterial gastritis, gastric ulcer | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| — | NCT05152004 | Sep 2018 → Nov 2021 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT03320538 | Jul 2017 → Sep 2020 | peptic ulcer disease | Jiangxi University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT04061447 | Feb 2016 → May 2019 | Helicobacter pylori infectious disease | Kaohsiung Medical University | Completed | No outcome recorded |
| — | NCT02149914 | May 2014 → Jul 2016 | Barrett esophagus, gastroesophageal reflux disease | Taichung Tzu Chi Hospital | Unknown | No outcome recorded |
| — | NCT02547025 | Aug 2012 → Oct 2021 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01139645 | Oct 2009 → Jul 2010 | calcium metabolic disease | American University of Beirut Medical Center | Completed | No outcome recorded |
| — | NCT00539786 | Mar 2006 → Apr 2011 | gastroesophageal reflux disease | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00234117 | Jul 2005 → ? | asthma, gastroesophageal reflux disease | Ponce Gastroenterology Research | Completed | No outcome recorded |
| — | NCT00517114 | Jan 2005 → Dec 2008 | gastroesophageal reflux disease, laryngitis | Hospital Authority, Hong Kong | Completed | No outcome recorded |
| — | NCT00162877 | Jun 2004 → Apr 2005 | active peptic ulcer disease, gastritis | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00517270 | Mar 2003 → Apr 2008 | intermediate coronary syndrome | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 85 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07339956 Background | Jan → Aug 2026 overdue | — | China-Japan Friendship Hospital | Not yet recruiting | No outcome recorded |
| Phase 116 trials | ||||||
| Phase 1 | NCT07643272 Background | Jun → Oct 2026 expected | — | Hutchmed | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07329972 Background | Nov → Dec 2025 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT07171619 Comparator | Aug → Nov 2025 | — | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT06916143 Background | Apr 2025 → Aug 2026 overdue | — | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06899061 Comparator | Mar 2025 → Feb 2026 overdue | high grade malignant neoplasm | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06787131 Background | May 2024 → Jul 2025 | — | Lomond Therapeutics Holdings, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04944771 Background | Jul 2021 → May 2022 | hematopoietic and lymphoid cell neoplasm | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04645940 Background | Sep → Nov 2020 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT04510649 Background | Jul → Sep 2020 | — | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 1 | NCT04471922 Comparator | Mar 2019 | — | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06337604 Background | Oct → Nov 2017 | Helicobacter pylori infectious disease | TenNor Therapeutics Limited | Completed | No outcome recorded |
| Phase 1 | NCT03237741 Background | Aug → Dec 2017 | amyotrophic lateral sclerosis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02699710 Background | Sep 2015 → May 2016 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01398046 Background | Aug 2011 → Feb 2014 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1 | NCT01153659 Comparator | Jul → Aug 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01085695 Comparator | Apr → May 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06076681 Background | Sep 2021 → Jan 2022 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT05604261 Comparator | Dec 2022 → Jul 2023 | dyskinesia of esophagus, gastroesophageal reflux disease, peptic esophagitis | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04503629 Comparator | Oct 2018 → May 2019 | duodenal ulcer | Sihuan Pharmaceutical Holdings Group Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT02637557 Background | Mar 2016 → Apr 2017 | gastroesophageal reflux disease | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02463643 Comparator | May 2015 → Oct 2016 | gastroesophageal reflux disease | Zeria Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT01805934 Comparator | May → Dec 2012 | — | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01513785 Comparator | Apr → Oct 2011 | dyspepsia | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00978016 Background | Sep 2009 → Dec 2010 | gastroesophageal reflux disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01002443 Comparator | Jul 2003 → Mar 2006 | gastric cancer | National Cancer Center, Korea | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT02847455 Comparator | Aug 2008 → Oct 2009 | duodenal ulcer | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00539240 Comparator | Apr 2006 → Apr 2010 | gastroesophageal reflux disease | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase 2/3 | NCT00204698 Comparator | Aug 2003 → May 2006 | upper respiratory tract disorder | University of Utah | Completed | No outcome recorded |
| Phase 313 trials | ||||||
| Phase 3 | NCT07608536 Comparator | May → Jul 2026 overdue | esophageal varices | King George's Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07010107 Comparator | Jul 2025 → Apr 2026 overdue | peptic esophagitis | Xuanzhu Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05857163 Background | May → Dec 2023 | Helicobacter pylori infectious disease | TenNor Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03779074 Comparator | Sep 2018 → Dec 2021 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 3 | NCT02368470 Background | Feb → Aug 2015 | Helicobacter pylori infectious disease | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT03658473 Comparator | Nov 2014 | stomach disorder | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 3 | NCT02767479 Comparator | Jul 2012 → Apr 2016 | Helicobacter pylori infectious disease | Hamamatsu University | Completed | No outcome recorded |
| Phase 3 | NCT01391715 Comparator | Aug 2011 → Oct 2012 | gastroesophageal reflux disease | Inje University | Withdrawn | No outcome recorded |
| Phase 3 | NCT01408186 Comparator | Jan 2011 → Nov 2015 | peptic ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT01140828 Comparator | May 2009 → Oct 2012 | dyspepsia, osteoarthritis, rheumatoid arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00857597 Comparator | Mar 2009 → Dec 2011 | gastroesophageal reflux disease | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 3 | NCT01051388 Comparator | Aug 2008 → Jul 2010 | cardiovascular disorder | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | Completed | No outcome recorded |
| Phase 3 | NCT02407119 Comparator | Jun 2003 → Jun 2016 overdue | Helicobacter pylori infectious disease, gastric carcinoma | National Cancer Center, Korea | Active not recruiting | No outcome recorded |
| Phase 432 trials | ||||||
| Phase 4 | NCT07122024 Comparator | Feb 2024 → Aug 2025 overdue | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT06168214 Comparator | Sep 2023 → Nov 2024 overdue | — | Xijing Hospital of Digestive Diseases | Recruiting | No outcome recorded |
| Phase 4 | NCT05879029 Background | Jul 2023 → Dec 2024 | upper respiratory tract disorder | Tongji Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05718609 Background | Mar 2023 → Mar 2024 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05014334 Comparator | Dec 2021 → Mar 2022 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT05023577 Background | Aug 2021 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05018923 Background | Aug 2021 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05191888 Comparator | Aug 2021 → Dec 2024 | active peptic ulcer disease | Kaohsiung Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT04416581 Comparator | May 2021 → Dec 2027 expected | acute coronary syndrome, coronary artery disorder, myocardial infarction | Duk-Woo Park, MD | Recruiting | No outcome recorded |
| Phase 4 | NCT04697186 Comparator | Jan → Dec 2021 | Helicobacter pylori infectious disease, chronic gastritis, dyspepsia, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04660123 Background | Dec 2020 → Dec 2021 | Helicobacter pylori infectious disease, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04667299 Background | Dec 2020 → Nov 2021 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04209933 Comparator | May → Aug 2020 | Helicobacter pylori infectious disease, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT03997279 Background | Jun 2019 → Jun 2020 | Helicobacter pylori infectious disease | Clinical Centre of Serbia | Unknown | No outcome recorded |
| Phase 4 | NCT03908619 Comparator | Apr 2019 → Mar 2021 | Helicobacter pylori infectious disease | Changi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03658746 Background | Jan → Dec 2019 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT03658733 Comparator | Dec 2018 → Aug 2019 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03094416 Background | Jul 2018 → Jun 2020 | postsurgical hypothyroidism | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 4 | NCT03521726 Background | May 2018 → Feb 2019 | Helicobacter pylori infectious disease | Mackay Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04132479 Comparator | Jan → Dec 2018 | Helicobacter pylori infectious disease | Kirby Institute | Completed | No outcome recorded |
| Phase 4 | NCT02986685 Background | Nov 2016 → Oct 2017 | peptic esophagitis | Xijing Hospital of Digestive Diseases | Withdrawn | No outcome recorded |
| Phase 4 | NCT02776371 Background | Sep 2016 → Jan 2018 | — | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT02638584 Comparator | Dec 2015 → Mar 2018 | gastric cancer | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT03108287 Background | Apr 2013 → Jan 2015 | Helicobacter pylori infectious disease | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01572597 Background | Jun 2011 → Dec 2012 | Helicobacter pylori infectious disease | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01573975 Background | Jan 2009 → May 2011 | Helicobacter pylori infectious disease | Buddhist Tzu Chi General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01967329 Comparator | Nov 2008 → May 2019 | Helicobacter pylori infectious disease | University of Alberta | Completed | No outcome recorded |
| Phase 4 | NCT01575899 Comparator | Dec 2007 → Dec 2009 | Helicobacter pylori infectious disease | Buddhist Tzu Chi General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00464308 Comparator | Nov 2006 → May 2008 | gastroesophageal reflux disease | Janssen-Cilag Pty Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00125736 Background | Aug 2005 → Apr 2007 | gastric ulcer | Eisai Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00354757 Comparator | Jun 2005 → Jun 2008 | gastroesophageal reflux disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00251732 Comparator | Mar 2005 → May 2010 | gastroesophageal reflux disease | University of Arizona | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT07358130 Comparator | Oct 2025 → Nov 2027 expected | Helicobacter pylori infectious disease | Kaohsiung Medical University | Recruiting | No outcome recorded |
| — | NCT07165444 Comparator | Sep 2025 → Feb 2026 overdue | Helicobacter pylori infectious disease, proton-pump inhibitor-responsive esophageal eosinophilia | Tanta University | Recruiting | No outcome recorded |
| — | NCT06349486 Comparator | Nov 2023 → Dec 2026 expected | — | Kaohsiung Medical University | Recruiting | No outcome recorded |
| — | NCT06004401 Comparator | Aug 2023 → Aug 2025 | — | Shanghai Changzheng Hospital | Unknown | No outcome recorded |
| — | NCT04723472 Background | Aug 2023 → Dec 2025 | Helicobacter pylori infectious disease | Shanghai East Hospital | Suspended | No outcome recorded |
| — | NCT05320133 Background | Jun 2022 → Nov 2024 | Helicobacter pylori infectious disease | Peking University First Hospital | Unknown | No outcome recorded |
| — | NCT02826408 Comparator | Oct 2016 → Mar 2018 | — | Jordan Collaborating Cardiology Group | Completed | No outcome recorded |
| — | NCT01643785 Background | Jun 2012 → Jun 2013 | Helicobacter pylori infectious disease | Chuncheon Sacred Heart Hospital | Terminated | No outcome recorded |
| — | NCT01237353 Background | Mar → Jul 2011 | — | University of California, San Francisco | Completed | No outcome recorded |
| — | NCT01037491 Comparator | Oct 2009 → Dec 2010 | duodenal ulcer, gastric ulcer | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| — | NCT00681005 Comparator | Apr 2006 → Jan 2008 | gastroesophageal reflux disease | National Taiwan University Hospital | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2007-05-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update on Generic Aciphex® Litigation tevapharm.com ↗ |
| 2006-02-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Rabeprazole Sodium Delayed-Release Tablets tevapharm.com ↗ |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 237 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabeprazole | “Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40...” NCT00978016 ↗224“This phase 1, open-label crossover study evaluated the relative bioavailability of dacomitinib in healthy volunteers under fed and fasted conditions and following...” PMID 26179237 ↗ Oct 2015 “Each subject will receive four single oral doses of 100 mg PF-06463922 as tablets alone, tablets with food, tablets with rabeprazole, and oral solution after overnight fasting...” NCT02569554 ↗ “Subjects will receive Rabeprazole 20 mg QD (fasted) at 2 hours before administration of 100 mg acalabrutinib tablet (Variant 1) and following prior administration of...” NCT04488016 ↗ “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “Bismuth potassium citrate:given for 14 days at a dose of bismuth potassium citrate 220 mg 0 BID,rabeprazole 10 mg BID, amoxicillin 1000 mg BID, and clarithromycin 500 mg BID” NCT04209933 ↗ “in Part A, all subjects will receive Surufatinib 300 mg in a single dose on study days 1 and 11 and receive Rabeprazole 30 mg single dose on study days 5 through 11” NCT04510649 ↗ “rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid” NCT01566643 ↗ “rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.” NCT01573975 ↗ “H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.” NCT02776371 ↗ “Subjects will receive the rabeprazole 10mg, moxycillin 1.0g, clarithromycin 500mg and Jinghua Weikang Capsule 240mg twice daily for 14 days.” NCT05320133 ↗ “rabeprazole 20 mg b.i.d. plus tripotassium dicitrate bismuthate 300 mg, tetracycline 500 mg and metronidazole 250 mg q.i.d. for 10 days” NCT03779074 ↗ “A single dose of 20 mg rabeprazole will be administered with 240 mL water, 2 hours prior to administration of acalabrutinib suspension.” NCT04435483 ↗ “Initial H pylori eradication with triple therapy (rabeprazole 20 mg qd, amoxicillin 1gm bid, clarithromycin 500 mg bid) for two weeks.” NCT02934152 ↗ “Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)” NCT01397448 ↗ “10 days tailored therapy including one Proton Pump Inhibitor ( Rabeprazole 0.4-0.5mg/kg.d,bid. or Esomeprazole 0.8-1.0mg/kg.d,bid)” NCT02635191 ↗ “Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.” NCT07165444 ↗ “The regimen contains rabeprazole 20mg bid, colloidal bismuth pectin 200mg bid, and two sensitive antibiotics determined by AST.” NCT03565484 ↗ “clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days” NCT05332444 ↗ “10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d” NCT01572597 ↗ “followed by rabeprazole (20 mg), clarithromycin (500 mg) and tinidazole (500 mg) twice daily for the remaining 5 days” PMID 12641522 ↗ Mar 2003 “Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.” NCT01575899 ↗ “including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).” NCT01805934 ↗ “Qingre Huashi Granules 1 package twice daily, Rabeprazole 20mg triple daily, Amoxycillin 1g triple daily.” NCT05364619 ↗ “Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days” NCT01002443 ↗ “Participants will receive 100 mg AT suspension in water via NG administration plus 20 mg rabeprazole.” NCT04564040 ↗ “rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.” NCT04061447 ↗ “PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg)” NCT01643785 ↗ “Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)” NCT01967329 ↗ “Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).” NCT04660123 ↗ “Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets” NCT03037606 ↗ “Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily” NCT02368470 ↗ “omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole” NCT03094416 ↗ “The comparator arm will receive Rabeprazole 20 mg once a day for 2 weeks.” NCT07608536 ↗ “Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole” NCT07611162 ↗ “rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily” NCT03108287 ↗ “Daily use of pantoprazole magnesium, rabeprazole or lansoprazole” NCT07076914 ↗ “20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)” NCT00251732 ↗ “Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5” NCT01153659 ↗ “clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week” NCT01023360 ↗ “rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days” NCT01163435 ↗ “one proton pump inhibitor: rabeprazole 10mg bid for 14d” NCT03658746 ↗ “rabeprazole 20mg qid,amoxicillin 750mg qid for 14days” NCT01265069 ↗ “Rabeprazole 20 mg 2x1, for 14 days” NCT03997279 ↗ “PPI (rabeprazole 20mg once daily)” PMID 40188976 ↗ Apr 2025 “Group R (rabeprazole 10 mg)” NCT02703896 ↗ “PPI: Rabeprazole 10mg bid” NCT06168214 ↗ “Rabeprazole 20mg bid po” NCT04723472 ↗ “Rabeprazole sodium” NCT01860482 ↗ “Drug: Rabeprazole” NCT05624229 ↗ “Rabeprazole 5mg” NCT05699070 ↗ “rabeprazole” NCT00165841 ↗ “Rabeprazole” NCT02149914 ↗ “Rabeprazole” NCT00857597 ↗ |
| Known as | Aciphex | “This study will also investigate the effect of Rabeprazole, (brand name Aciphex) on patients with known insomnia.” NCT00287391 ↗ |
| Known as | Aciphex sprinkle | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | E-3810 (PPI) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | E-3810 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | E3810 | “Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)” NCT01397448 ↗ |
| Known as | Eraloc | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Idiazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | LY-307640 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | LY307640 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | NSC-759270 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Pariet | “To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal...” NCT00165646 ↗4“1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily” NCT01139645 ↗ “High Dose Rabeprazole (Pariet) in the Treatment” NCT00517114 ↗ “Rabeprazole(Pariet) for 7 days.” NCT01575899 ↗ |
| Known as | Pariet (rabeprazole) | “Pariet (rabeprazole)” NCT02037477 ↗1“Pariet(rabeprazole)” NCT00844675 ↗ |
| Known as | Pariprazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Proton pump inhibitor, Rabeprazole, Pariet | “Proton pump inhibitor, Rabeprazole, Pariet®” NCT03897244 ↗ |
| Known as | Rabeprazol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Rabeprazole Enteric-Coated Tablets | “Rabeprazole Enteric-Coated Tablets10mg once a day for 2 weeks” NCT07339956 ↗ |
| Known as | Rabeprazole ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00839306 ↗ |
| Known as | Rabeprazole na | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Rabeprazole sodium | “To investigate the efficacy and safety of a 4-week treatment of 5 mg/day or 10 mg/day of E3810 (Pariet (Rabeprazole Sodium)) in patients with non-erosive gastroesophageal...” NCT00165646 ↗12“All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “Patients will receive rabeprazole sodium as single daily oral doses for 5 successive days (Option 1), or up to 14 successive days (10 days minimum) (Option 2) as a bead formulation.” NCT00747526 ↗ “Rabeprazole sodium enteric-coated tablets (20 mg BID): Taken with 240 mL of warm water 30 minutes (± 5 minutes) before breakfast and dinner for 14 consecutive days.” NCT06337604 ↗ “The drug being studied is rabeprazole sodium, the active pharmaceutical ingredient in AcipHex.” NCT00855361 ↗ “rabeprazole sodium in healthy volunteers” NCT01101646 ↗ “Rabeprazole Sodium Tablets 20 mg” NCT00649493 ↗ “Rabeprazole sodium 10mg” NCT04503629 ↗ |
| Known as | Rabeprazole sodium enteric-coated tablets | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481371 ↗ |
| Known as | Rabeprazole sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Known as | Rabeprazole: Pariet | “Rabeprazole: Pariet” NCT01219764 ↗ |
| Known as | Sodium rabeprazole | ChEMBL registry synonym — accepted as the source's own label CHEMBL1219 ↗ |
| Action | Inhibit | “These measurement will be used to compare the degree of inhibition of gastric acid secretion between the two drugs.” NCT00304421 ↗ |
| Modality | Small molecule | “rabeprazole, which is a newly developed benzimidazole proton pump inhibitor” NCT00517270 ↗ |
| Route | Oral | “One 10mg tablet is administered orally each day” NCT00125736 ↗ |